VA Medical Marijuana Research: Veterans, PTSD, Chronic Pain and Federal Policy

Executive summary

A new congressional bill would direct the Department of Veterans Affairs (VA) to study whether medical marijuana helps veterans with post-traumatic stress disorder (PTSD) and chronic pain, and it would end a decades-long gap between veteran demand and VA-generated evidence. Marijuana Moment reported the bill on October 1, 2026. This hub covers the policy backdrop and will absorb dated updates as the bill moves.

VA clinicians still cannot recommend cannabis or complete state medical marijuana paperwork, because marijuana remains a Schedule I substance under 21 U.S.C. § 812. Under VHA Directive 1315, veterans are not denied VA benefits for state-legal use, and they are encouraged to tell their care teams about it. The VA has funded little of its own cannabis clinical research. Most of the evidence on veterans comes from non-VA investigators, observational data and state-program surveys.

The research mandate sits inside a larger federal shift. HHS recommended moving marijuana to Schedule III in 2023. The DEA published an NPRM in May 2024, and the rulemaking later stalled in an ALJ hearing process. Rescheduling would not authorize VA prescribing on its own. It would change research logistics and tax treatment under 280E for state-licensed operators.

The bill text, sponsors and cosponsors should be confirmed on Congress.gov. This page does not characterize provisions beyond the headline reporting. The practical stakes are clear:

• About 7 of every 100 veterans will have PTSD at some point, according to the VA's National Center for PTSD.
• Chronic pain is among the most common conditions in VA primary care.
• Roughly 40 states now run medical cannabis programs that veterans can legally use outside the VA system.

Why this matters

Veterans are using cannabis in large numbers without VA-generated data on dose, safety or outcomes, and a research mandate would give clinicians, regulators and state programs a federal evidence base.

Patients

The VHA enrolls roughly 9 million veterans, and the U.S. veteran population is about 18 million. PTSD and chronic pain frequently co-occur, and both are major drivers of opioid exposure, benzodiazepine use and suicide-risk conversations. Veterans who use cannabis for these conditions currently do so without VA clinician guidance on products, dosing or drug interactions.

The American Legion commissioned a 2017 Iowa State University survey of its members. According to the Legion, the survey found that a substantial minority of respondents said they used or knew someone who used cannabis for medical conditions, and that an overwhelming majority supported federal research and access. The Legion has since pressed Congress to reschedule marijuana to allow research.

Clinicians and the VA

VA providers sit in a bind. They are federal employees prohibited from recommending a state-legal product, yet they must manage patients who use it. A VA study would create an in-house evidence stream, and could inform the VA/DoD clinical practice guidelines, which do not list cannabis among recommended PTSD treatments.

Operators and investors

Veterans are a built-in patient cohort for medical programs in states such as Florida, Pennsylvania, Texas and Ohio. Federal evidence on PTSD and pain would strengthen the case for qualifying-condition lists, product standards and insurer or workers' compensation reimbursement debates. It would not change wholesale pricing by itself. It would shift the long-run narrative from "recreational" to "clinical," which matters for banking, MSO capital access and any 280E relief.

Federal budget

A research mandate carries appropriations questions: who funds trials, how much, and through which VA research office. Mandates without dedicated funding tend to produce slow, narrow studies. Appropriations language, not authorizing language, usually decides whether research happens.

Background and history

The VA's cannabis posture is the product of a century of federal prohibition, a 2010s wave of state medical laws, and repeated congressional attempts to let VA doctors engage.

1937–1970: Prohibition and Schedule I

The Marihuana Tax Act of 1937 effectively criminalized cannabis federally. The Controlled Substances Act of 1970 (21 U.S.C. § 801 et seq.) placed marijuana in Schedule I, defined as a drug with a high abuse potential, no accepted medical use and a lack of accepted safety under medical supervision. Every federal agency, including the VA, has operated under that classification since.

1996: California opens the state-law track

California's Proposition 215 legalized medical use in 1996 and started a state-by-state expansion. Veterans were among the early patient populations, and PTSD later became a qualifying condition in many states. State programs created a legal market the federal government did not recognize.

2005: Gonzales v. Raich

In Gonzales v. Raich (2005), the Supreme Court held that Congress may regulate intrastate, noncommercial cannabis under the Commerce Clause. State medical laws therefore provide no federal defense, and federal employers such as the VA remain bound by the CSA.

2011–2017: VA policy takes shape

The VHA issued a 2011 directive on veterans participating in state marijuana programs. It was reissued in 2017 as VHA Directive 1315. It lets veterans keep VA benefits while using state-legal cannabis. VA providers must record use in the medical record and discuss it with patients. They may not recommend cannabis or complete state-program forms. The directive also bars VA pharmacies from dispensing it.

2016–present: Congress tries to open the door

In 2016, the Senate adopted an amendment to a military construction and VA appropriations bill that would have let VA physicians discuss and recommend state-legal medical cannabis. The House stripped it in conference. Variants of the proposal, often called the Veterans Equal Access Act, have recurred in several cycles. The House has adopted versions in appropriations or defense bills, and they did not survive final negotiations.

2018–2021: Epidiolex and the first VA-adjacent trials

In 2018, the FDA approved Epidiolex, a purified CBD medicine for certain seizure disorders. That showed a cannabinoid could clear the drug-approval bar. The FDA had previously approved dronabinol and nabilone, synthetic THC-based drugs, for nausea and appetite indications.

Dr. Sue Sisley, working with the Multidisciplinary Association for Psychedelic Studies (MAPS), led a randomized crossover trial of smoked cannabis for PTSD in military veterans. The results were published in 2021 in PLOS ONE. The trial was not VA-run, and it used federally supplied flower. The study illustrated both the feasibility of veteran cannabis trials and the barriers to running them.

2017: National Academies review

The National Academies of Sciences, Engineering, and Medicine published The Health Effects of Cannabis and Cannabinoids in 2017. It found substantial evidence that cannabis is effective for chronic pain in adults, and that evidence for PTSD was limited. That split, strong on pain and thin on PTSD, still frames the debate.

2022: Research barriers eased

Frequently asked questions

Does the VA currently study medical marijuana for veterans?

VA-run research on cannabis has been very limited, largely because of federal Schedule I restrictions on obtaining and handling the substance. Congress has repeatedly pushed the department to do more, and the newest bill reported by Marijuana Moment would require the VA to study cannabis for veterans with PTSD and chronic pain.

What does the new congressional bill propose?

According to Marijuana Moment, the bill would require the VA to conduct research on the potential benefits of medical marijuana for veterans with PTSD and chronic pain. Like all bills, it must pass committee review and both chambers and be signed into law before it takes effect. Check Congress.gov for current status.

Can VA doctors prescribe or recommend medical marijuana?

No. VA policy prohibits VA clinicians from prescribing cannabis or recommending it, and from completing the paperwork veterans need to enroll in state medical cannabis programs. Veterans must seek recommendations from non-VA, state-licensed providers where programs exist.

Will I lose my VA benefits if I use state-legal cannabis?

VA policy states that veterans will not be denied VA benefits because of cannabis use. Veterans are encouraged to tell their VA providers about use so it can be factored into their care and checked for interactions with other medications.

Why has VA cannabis research been so limited?

Cannabis is a Schedule I controlled substance under federal law, which makes research difficult. Studies need DEA registration and, historically, cannabis supplied through a single federally authorized source, the University of Mississippi. The VA is a federal agency bound by those rules.

Does cannabis help treat PTSD?

The evidence is not yet conclusive. Some observational studies and small trials suggest symptom relief for some patients, but high-quality randomized trials are limited. This gap is a core reason lawmakers and veterans' groups call for VA-backed research. Cannabis is not an FDA-approved PTSD treatment.

Does cannabis help with chronic pain in veterans?

Reviews, including the 2017 National Academies of Sciences report, found substantial evidence that cannabis is effective for chronic pain in adults. Research specific to veterans is sparser, and risks such as dependence and cognitive effects must be weighed. Patients should consult a clinician.

How does federal rescheduling affect VA research?

Moving cannabis out of Schedule I would ease registration and supply barriers for researchers, potentially including VA investigators. It would not by itself change VA prescribing policy, which would require separate departmental or legislative action.

What have past VA cannabis bills tried to do?

Past proposals in Congress have sought to let VA doctors recommend medical cannabis in legal states and to direct clinical trials on cannabis for PTSD and pain. Several have been introduced or attached to appropriations bills, but none have been enacted as standalone law. Check Congress.gov for current status.

How can veterans access medical cannabis today?

Veterans in states with medical programs can obtain a recommendation from a state-licensed non-VA clinician and register under that state's rules. Costs are generally out of pocket, since the VA does not pay for medical cannabis. Rules vary by state.

veteransVA policyPTSDchronic paincannabis researchfederal legislation